Additional analysis reveals some benefits with Gammagard Liquid (Baxter) in Alzheimers Disease

Additional analyses from a negative Phase III clinical trial of Gammagard Liquid/Kiovig (intravenous immunoglobulin), from Baxter, in people with mild to moderate Alzheimer's disease shows participants in the APOE-e4 carrier subgroup had numerically superior results at 18 months relative to placebo on the Modified Mini-Mental State Examination and the Trails B test, two out of several measures of thinking ability made in the study. Baxter announced topline results of the first Phase III clinical trial of IVIG in May 2013 which did not meet its primary endpoint.

However this analysis shows that in addition, statistically significant, dose dependent reductions in plasma beta-amyloid 42 levels (but not beta-amyloid 40) were observed in IVIG treated patients relative to placebo. Biomarker analyses also demonstrated that antibodies from the treatment reached the central nervous system. Data were presented at the Alzheimer's Association International Conference.